ライフサイエンスコーパス: IL-13R

1 IL-13R has not previously been reported to be functional

2 IL-13R-negative cell lines or cell lines expressing low

3 onsistent with its lower affinity for IL-13, IL-13R alpha 1.Fc was 100-fold less effective than IL-13

4 ional high affinity binding chain for IL-13, IL-13R alpha 2, has been described in humans.

5 R is augmented and that the endogenous IL-13-IL-13R pathway contributes to the induction of inflammat

6 re, we show that the IL-13 receptor alpha 2 (IL-13R alpha 2) is a critical mediator of immune down-mo

7 els, and Stat6 activation by the common IL-4/IL-13R drives most mouse model pathophysiology, includin

8 ownstream targets of molecules that activate IL-13R and EGFR and are responsible for mucus production

9 th NASH express high levels of high-affinity IL-13R (IL-13Ralpha2), which is colocalized with smooth

10 s the apoptosis of Th1 cells via IL-4R alpha/IL-13R alpha 1, thus explaining the Th2 bias in neonates

11 ommon gamma-chain (gamma(c)) and IL-4R alpha/IL-13R alpha1, and only the latter is also activated by

12 (IL-4R alpha/IL-13R alpha1/IL-4, IL-4R alpha/IL-13R alpha1/IL-13) ternary signaling complexes.

13 lpha/gamma(c)/IL-4) and type II (IL-4R alpha/IL-13R alpha1/IL-4, IL-4R alpha/IL-13R alpha1/IL-13) ter

14 gh levels of interleukin 13 receptor alpha1 (IL-13R alpha 1), which heterodimerizes with IL-4R alpha.

15 Interleukin 13 receptor alpha2 (IL-13R(alpha)2) chain is highly expressed on some tumor

16 13 production results in the induction of an IL-13R formerly thought to function only as a decoy rece

17 f binding and stabilization of the IL-4R and IL-13R complexes, we compared the effects of shIL-4Ralph

18 IL-13 and IL-4 are homologues and IL-4R and IL-13R have been proposed to share a receptor subunit, I

19 important role in the function of IL-4R and IL-13R in colon cancer cells.

20 to the yC and IL-13Ra1 subunits of IL-4R and IL-13R, respectively, and dephosphorylate IL-4Ra, dampen

21 it from binding to and inhibiting IL-4R and IL-13R.

22 ession of interleukin-4 receptor (IL-4R) and IL-13R subunits.

23 R beta chain (also known as IL-4R alpha) and IL-13R alpha' chain (also known as IL-13R alpha1).

24 n growth between vector only transfected and IL-13R(alpha)2 chain transfected cells in vitro.

25 lpha) and IL-13R alpha' chain (also known as IL-13R alpha1).

26 s a key role in the binding affinity of both IL-13R and IL-4R complexes.

27 L-4R and a low affinity IL-13-binding chain, IL-13R alpha 1, have been cloned in mice and humans.

28 We recently described IL-13R expression on human renal cell and colon carcinom

29 To target tumor cells that express IL-13R, we have produced a chimeric protein composed of

30 acts through a novel cell surface-expressed IL-13R to induce TGF-beta(1).

31 ious solid tumor cell lines that express few IL-13Rs can dramatically sensitize cells to the cytotoxi

32 y, in designing specific targeted agents for IL-13R-positive malignancies.

33 e shown that Th17 cells express a functional IL-13R and that IL-13 negatively regulates IL-17A and IL

34 s murine IL-4Ralpha to generate a functional IL-13R.

35 Our studies have defined the functional IL-13R complex, association of Jaks with the receptor co

36 Furthermore, IL-13R(alpha)2 chain overexpressing tumors constitutivel

37 t encodes the murine orthologue of the human IL-13R alpha 2.

38 R alpha 2) has 59% overall identity to human IL-13R alpha 2 and is closely related to the murine low

39 utrophils and macrophages were identified in IL-13R(alpha)2 overexpressing regressing tumors and neut

40 , tumorigenicity was profoundly inhibited in IL-13R(alpha)2 chain overexpressing tumors.

41 edict distinct roles for each polypeptide in IL-13R complex formation and in the modulation of IL-13

42 Addition of IL-13 at polarization increased IL-13R expression in wild-type Th17 cells.

43 s revealed CD33(+)CD11b(+)CD66b(+)HLA-DR(low)IL-13R alpha2(int) large mononuclear cells with abundant

44 -MDSC and MDSC miR-126a(+) exosomes via MDSC IL-13R.

45 The predicted protein sequence of murine IL-13R alpha 2 (mIL-13R alpha 2) has 59% overall identit

46 ted on the expression and characteristics of IL-13R and have demonstrated that IL-13 competes for IL-

47 monstrated that gammac is not a component of IL-13R or IL-4R systems in these cells.

48 -4R but does not appear to be a component of IL-13R.

49 rein, we examined the subunit composition of IL-13R by analyzing the expression of four different put

50 QR correlated positively with the density of IL-13R.

51 The extracellular domain of IL-13R alpha2 (ECD alpha2) could be cleaved, which serve

52 is lack of IL-12 sustained the expression of IL-13R alpha 1 on Th1 cells.

53 ave increased mRNA and protein expression of IL-13R alpha1 and mRNA expression of IL-4R alpha compare

54 Based on the expression of IL-13R, we have classified five head and neck cancer cel

55 ropose that there are at least four forms of IL-13R.

56 t tumor-bearing mice led to the induction of IL-13R(+)miR-126a(+) MDSCs (DOX-MDSC).

57 ity of cell lines express only low levels of IL-13R.

58 breast tumors that grew later showed loss of IL-13R(alpha)2 gene expression, lack of tumorigenicity c

59 ines or cell lines expressing low numbers of IL-13R ( < 300 sites/cell) that include human bone marro

60 L-12, which triggered the down-regulation of IL-13R alpha 1 expression on Th1 cells, thus protecting

61 ity, require activation for up-regulation of IL-13R constituents.

62 ssion of four different putative subunits of IL-13R complex in 25 primary explants of malignant brain

63 rmal brain tissue showed that transcripts of IL-13R alpha chain were present in greater abundance in

64 ize an unusual top-mounted Ig-like domain on IL-13R alpha1 for a novel mode of cytokine engagement th

65 unction in some cell types, its influence on IL-13R function in tumor cells appear to be largely nega

66 affinity IL-13-binding transmembrane protein IL-13R(alpha)2 that inhibited IL-13-mediated Stat6 activ

67 nstrated a critical role for IL-13 receptor (IL-13R) alpha1 in allergen-induced airway responses.

68 hown that the decoy receptor IL-13 receptor (IL-13R) alpha2 attenuates responses of fibroblasts to IL

69 The interleukin-13 receptor (IL-13R) complex is composed of 2 different chains, IL-13

70 3Ralpha1, a component of the IL-13 receptor (IL-13R), as a novel ligand of integrin Mac-1, using a co

71 ress high levels of interleukin-13 receptor (IL-13R).

72 Although interleukin-13 receptors (IL-13R) are overexpressed on several head and neck cance

73 s large numbers of interleukin-13 receptors (IL-13R), a newly described hemopoietic growth factor rec

74 role in the interaction with its receptors (IL-13R).

75 indistinguishable in control-Fc- and soluble IL-13R alpha2-Fc fusion protein-treated animals.

76 ade of the Th2 cytokine IL-13, using soluble IL-13R alpha2-Fc fusion protein, significantly reduced t

77 e murine low affinity IL-13-binding subunit, IL-13R alpha 1.

78 alpha 1.Fc was 100-fold less effective than IL-13R alpha 2.Fc in neutralizing IL-13 in vitro.

79 We have recently reported that IL-13R may share a component with IL-4R.

80 al human astrocytes that did not express the IL-13R(alpha)2 gene efficiently induced Stat6 activation

81 pha' chain (termed IL-13Ralpha') but not the IL-13R alpha chain (termed IL-13Ralpha) can substitute f

82 lleled by a loss of expression of one of the IL-13R chains and intercellular cell adhesion molecule-1

83 in also participates in the formation of the IL-13R complex in some cell types.

84 lular differences in the distribution of the IL-13R components to the physiological regulation of smo

85 udies demonstrate that the expression of the IL-13R is augmented and that the endogenous IL-13-IL-13R

86 e propose that the 65- to 70-kDa form of the IL-13R is the predominant common component shared betwee

87 etween the short intracellular domain of the IL-13R(alpha)2 protein and the cytoplasmic domain of the

88 Transient expression of the IL-13R(alpha)2 transgene in nonexpressing heterologous c

89 To explore the complexity of the IL-13R, a wide variety of cell types was examined for IL

90 ents the expression of the components of the IL-13R, IL-13Ralpha1, and IL-4Ralpha.

91 ha with either the common gamma-chain or the IL-13R chain alpha1 (IL-13Ralpha1).

92 Here, we show that the IL-13R alpha' chain (termed IL-13Ralpha') but not the IL

93 temic or locoregional cytotoxin therapy, the IL-13R represents a new potent target for head and neck

94 e gammac chain may involve signaling via the IL-13R.

95 a-chain to form the type I IL-4R or with the IL-13R alpha1 chain (IL-13Ralpha1) to form the type II I

96 g IL-4Ralpha chain, which is shared with the IL-13R, and the IL-2Rgamma (gammac) chain, which is shar

97 Thus, IL-13R(alpha)2 acts as an inhibitor of IL-4-dependent si

98 IL-13 showed a modest antitumor activity to IL-13R(alpha)2 chain overexpressing tumors in vitro and

99 sitizing certain types of prostate tumors to IL-13R-directed therapeutic agent.

100 ression of this chain, we stably transfected IL-13R(alpha)2 chain in human breast (MDA-MB-231) and pa

101 ating xenograft tumor-bearing nude mice with IL-13R-directed cytotoxin (IL13-PE38QQR).

102 of tumorigenicity correlated positively with IL-13R(alpha)2 chain expression.

103 Treatment of these rats with IL-13R-directed cytotoxin caused a substantial decline i